-

Robbins LLP Announces 9F Inc. (JFU) Sued for Misleading Shareholders

SAN DIEGO & BEIJING--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action complaint was filed against 9F Inc. (NASDAQ: JFU) for violations of the Securities Act of 1933 on behalf of shareholders who acquired 9F Inc. shares pursuant to the Company's August 2019 initial public offering ("IPO"). 9F Inc., together with its subsidiaries, operates a digital financial account platform that integrates and personalizes financial services in the People's Republic of China.

If you have suffered a loss due to 9F Inc.'s misconduct, click here.

9F Inc. (JFU) Accused of Misleading Shareholders

9F conducted its IPO on August 15, 2019, selling over 8 million ADS shares for $9.50 per share. According to the complaint, the Registration Statement failed to disclose that 9F was in a dispute with its insurance partner, PICC, resulting in multiple legal actions in China. Further, the Registration Statement failed to disclose that PICC was challenging, delaying, and otherwise failing to pay service fees to 9F under the parties' agreement, rendering the collectability of services fees owed to 9F by PICC doubtful and as risk of non-payment.

On June 15, 2020, 9F stated it could not timely file its annual report with the SEC because of its dispute with PICC. The notice indicated that the Company's dispute with PICC predated its IPO and was expected to have significant impact on the results of its 2018 and 2019 operations. In addition, a press release issued on June 17, 2020, further reaffirmed that 9F's dispute with PICC predated the IPO and had caused material damage to 9F's business, operations, and financial results. By September 24, 2020, 9F traded at $0.80 at per share, a more than 90% decline from its IPO price.

9F Inc. (JFU) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against 9F settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Super Micro Computer, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers. For more information, submit a form,...

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...
Back to Newsroom